NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
This achievement highlights the remarkable seven-year progression of FLEX and its many sub-studies highlighting the ethnic and racial nuances that may influence treatment pathways. IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ September 12, 2024 Read More
Agendia Achieves CE-IVDR Certification
Agendia Achieves CE-IVDR Certification for its MammaPrint and BluePrint Breast Cancer Assays
Read MoreAgendia Announces JCO Publication on MammaPrint Utility in NRG/NSABP B-42 Trial
MammaPrint 70-gene Assay Evaluated in the NRG Oncology/NSABP B-42 Trial
Read MoreNewsroom
News, Stories & Breast Cancer Blog
How a Pregnant Woman Diagnosed With Breast Cancer Was Helped by MammaPrint
Aleseia Saunders was 32 when she felt a lump in her right breast. Being so young with no family history of breast cancer, she shrugged it off as being a cyst and went on Read More
Laura J. van โt Veer, PhD, Honored With 2024 William L. McGuire Memorial Lecture Award at SABCS 2024
SAN ANTONIO โ Laura J. van โt Veer, PhD, will receive the William L. McGuire Memorial Lecture Award during the San Antonio Breast Cancer Symposium (SABCS) 2024, to be held December 10-13 at the Read More
Gene Assay for MammaPrint May Predict Responses to Extended Letrozole in Low-Risk Breast Cancer Subsets
By Roman Fabbricatore | August 30, 2024 A gene assay was predictive of response to extended letrozole therapy, identifying a subset of patients with low-risk breast cancer with improved outcomes. The 70-Gene MammaPrint (MP) Read More
Personalized Breast Cancer Treatment Offered by Texas Breast Center Utilizes Agendia
Texas Breast Center, led by renowned breast surgeon Dr. Valerie Gorman, is pleased to announce the use of Agendia, a global leader in genomic testing. This collaboration aims to provide patients with the most Read More
Hormonal Therapy Story: How Laura-Lynn Renner Made an Informed Choice
By Kris Conner | August 7, 2024 How the diagnostic test MammaPrint empowered Laura-Lynn to find answers and advocate to improve the quality of her life. In the summer of 2020, Laura-Lynn Renner, a Read More
What Is Chemotherapy?
Along with surgery or radiation therapy, chemotherapy is one of the most common ways to treat cancer. Chemotherapy treatment is designed to destroy cancer cells; it can be used for primary cancer (cancer that Read More
Anthracycline Plus Chemo Associated With Improved RFS in MP High-2โRisk, HR+/HER2โ Early Breast Cancer
By Ryan Scottย June 1, 2024 Key Takeaways Patients with MammaPrint high-2, BluePrint Luminal B, HR-positive, HER2-negative early breast cancer had better 3-year RFS with anthracycline plus a taxane and cyclophosphamide. Luminal MP high-1โrisk Read More